Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carvedilol for Preventing Cardiac Toxicity in Metastatic HER-2+ Breast Cancer
NCT03418961Phase 3Recruiting
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2017
- Primary completion
- Jun 2031
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of carvedilol in Cardiotoxicity, sponsored by SWOG Cancer Research Network. Started Nov 2017; status: recruiting.
02
Drugs
carvedilol
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT03418961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03418961.